475 related articles for article (PubMed ID: 27722966)
1. Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.
Scheen AJ
Drug Saf; 2005 Jul; 28(7):601-631. PubMed ID: 27722966
[TBL] [Abstract][Full Text] [Related]
2. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
Scheen AJ
Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Scheen AJ
Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Scheen AJ
Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
[TBL] [Abstract][Full Text] [Related]
6. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
7. Antihyperglycaemic agents. Drug interactions of clinical importance.
Scheen AJ; Lefèbvre PJ
Drug Saf; 1995 Jan; 12(1):32-45. PubMed ID: 7741982
[TBL] [Abstract][Full Text] [Related]
8. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
Vos RC; van Avendonk MJ; Jansen H; Goudswaard AN; van den Donk M; Gorter K; Kerssen A; Rutten GE
Cochrane Database Syst Rev; 2016 Sep; 9(9):CD006992. PubMed ID: 27640062
[TBL] [Abstract][Full Text] [Related]
9. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
10. Management of antidiabetic medications in overdose.
Spiller HA
Drug Saf; 1998 Nov; 19(5):411-24. PubMed ID: 9825953
[TBL] [Abstract][Full Text] [Related]
11. Meglitinide analogues in the treatment of type 2 diabetes mellitus.
Landgraf R
Drugs Aging; 2000 Nov; 17(5):411-25. PubMed ID: 11190420
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced disorders of glucose metabolism. Mechanisms and management.
Chan JC; Cockram CS; Critchley JA
Drug Saf; 1996 Aug; 15(2):135-57. PubMed ID: 8884164
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
[TBL] [Abstract][Full Text] [Related]
14. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
15. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
Culy CR; Jarvis B
Drugs; 2001; 61(11):1625-60. PubMed ID: 11577798
[TBL] [Abstract][Full Text] [Related]
16. Glucose-lowering treatment of type 2 diabetes. Part II--Glucose-lowering drugs after metformin: a choice based largely on adverse effects.
Prescrire Int; 2015 May; 24(160):130-5. PubMed ID: 26034806
[TBL] [Abstract][Full Text] [Related]
17. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
18. Oral antidiabetic agents. A guide to selection.
Scheen AJ; Lefèbvre PJ
Drugs; 1998 Feb; 55(2):225-36. PubMed ID: 9506242
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic interactions with thiazolidinediones.
Scheen AJ
Clin Pharmacokinet; 2007; 46(1):1-12. PubMed ID: 17201456
[TBL] [Abstract][Full Text] [Related]
20. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
